The enzyme ribonucleotide reductase is a bottleneck for cancer cell growth. Scientists have identified a way of targeting ribonucleotide reductase that may avoid the toxicity of previous approaches, informing focused drug discovery efforts.
Click here for original story, Targeting old bottleneck reveals new anticancer drug strategy
Source: ScienceDaily